摘要
目的 探讨过氧化物酶体增殖物激活受体 (PPAR- γ)的配体——噻格列酮对人胆囊上皮细胞炎症的调控。方法 分离培养胆囊上皮细胞 ,建立胆囊上皮细胞炎症模型 ,检测对照组和噻格列酮组培养液中 IL- 6、TNF-α值及细胞形态学变化。结果 成功分离培养胆囊上皮细胞并建立胆囊上皮细胞炎症模型 ,细胞最长可存活 2 5 d。炎症对照组细胞肿胀、胞膜不清 ,胞浆混浊 ,添加噻格列酮后 ,细胞炎性水肿有不同程度减轻 ,以 5 0 μmol/ m l组最明显。噻格列酮组 IL- 6值明显低于对照组 (P<0 .0 1) ,差别最大达 179.85 pg/ m l,抑制效应与浓度呈正相关关系。结论 噻格列酮能抑制胆囊上皮细胞炎症 。
Objective To investigate the inflammatory regulation of human gallbladder epithelial cells (HGBEC) by peroxisome proliferator activated receptor gamma (PPAR-γ) ligand ciglitazone. Methods HGBEC were cultured in medium containing human epidermal growth factor (hEGF). HIL-1β were added into the ciglitazone groups and inflammatory control groups to make inflammatory model . IL-6 and TNF-α concentration in ciglitazone groups and all control groups were measured. Results HGBEC were cultured in medium successfully. The inflammatory model was made. The longest duration is 25 d. In inflammatory control groups, cells were edema with unclear cellular membrane and plasmid. In ciglitazone groups, the inflammatory edema of cells were less evident than that in inflammatory control groups, especially in 50 μmol/ml group. The IL-6 concentration in ciglitazone groups is lower than that in control group (P<0.01). The relation between the inhibitory effect and the concentration of ciglitazone is positive correlation. Conclusion Ciglitazone that can inhibit the inflammation of HGBEC maybe an effective treatment for acute and chronic cholecystitis.
出处
《四川大学学报(医学版)》
CAS
CSCD
北大核心
2004年第5期658-661,共4页
Journal of Sichuan University(Medical Sciences)
基金
教育部出国留学回国人员科研启动基金 [2 0 0 1( 3 45 ) ]资助